Search Results

You are looking at 91 - 100 of 295 items for :

Clear All
Full access

Lida Mina, Ruben G.W. Quek, Johannes Ettl, Ying Chen, Miguel Martin, Zev A. Wainberg, Johann S. de Bono, Sara A. Hurvitz and Hope S. Rugo

Background: TALA significantly improved progression-free survival versus physician’s choice chemotherapy (PCT) in patients (pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) in the randomized Phase (Ph) 3 EMBRACA

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Mohammad Jahanzeb, Krystyna Kiel, Britt-Marie Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lisle M. Nabell, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, George Somlo, Richard L. Theriault, Neal S. Topham, John H. Ward, Eric P. Winer and Antonio C. Wolff

; 27 : S215 – 229 . 22 Wang S Saboorian MH Frenkel E . Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays

Full access

Cesar A. Santa-Maria and Rita Nanda

they are classified by the presence or lack of endocrine receptors (ERs) and HER2. 8 , 9 Response rates to immunotherapy in breast cancer vary among the different clinical subtypes of breast cancer. Breast cancer subtypes are both genetically and

Full access

Antonio Di Meglio, Nancy U. Lin, Rachel A. Freedman, William T. Barry, Eric P. Winer and Ines Vaz-Luis

chart review were categorized as per Table 1 . Tumor subtypes were classified as hormone receptor (HR)+ (estrogen receptor [ER]+ and/or progesterone receptor [PR]+)/HER2−; HR+ (ER+ and/or PR+)/HER2+; HR− (ER− and PR−)/HER2+; and HR− (ER− and PR−)/HER2

Full access

Frederick D. Tsai and Robert I. Haddad

that salivary ductal carcinoma (SDC) histologically resembles breast adenocarcinoma led to the finding of HER2 expression in a subset of SDC, which responded well to inhibition with trastuzumab. 1 , 2 Indeed, the standard approach to treating patients

Full access

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Jasgit Sachdev, Mary Lou Smith, George Somlo, John H. Ward, Antonio C. Wolff and Richard Zellars

growth factor receptor 2 [HER2]). These factors are determined by examination of excised tissue and provided in a written pathology report. Accurate pathology reporting requires communication between the clinician and pathologist regarding relevant

Full access

Angela M. Davies, Philip C. Mack, Primo N. Lara Jr., Derick H. Lau, Kathleen Danenberg, Paul H. Gumerlock and David R. Gandara

. J Clin Oncol 2002 ; 20 ( Suppl 18 ): 1S – 13S . 31 Brabender J Danenberg KD Metzger R . Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival . Clin Cancer Res 2001

Full access

Metastatic Breast Cancer, Version 1.2012

Featured Updates to the NCCN Guidelines

Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, Stephen B. Edge, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Steven Jay Isakoff, Britt-Marie E. Ljung, David A. Mankoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, Hatem Soliman, George Somlo, Richard L. Theriault, John H. Ward, Antonio C. Wolff, Richard Zellars, Rashmi Kumar and Dorothy A. Shead

of retesting of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) in patients with recurrent disease; new information regarding first-line combination endocrine therapy for metastatic disease; a

Full access

Ali Raza Khaki, V.K. Gadi and Vinay Prasad

adjuvant chemotherapy to adjuvant endocrine therapy in women with localized hormone receptor (HR)–positive, HER2-negative disease. Generally, poor prognosis is predictive of benefit from chemotherapy (ie, a greater and meaningful absolute risk reduction in

Full access

Margaret Tempero

HER2 amplification. I was thrilled. This was actionable and gave us another option down the road. So when the time came, after standard therapy stopped working, we were able to get both trastuzumab and pertuzumab. We started treatment, but it didn